Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed ...

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

Disease characteristics, age, and geography are among the main factors that shape first-line treatment patterns in patients ...

Shorla Oncology® Announces U.S. FDA Approval of Larger Vial Size for Nelarabine Intravenous Administration for the Treatment of T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma ...

Pediatric non-Hodgkin’s lymphoma (NHL) is a type of cancer that may affect children. It occurs when cells in the immune system divide uncontrollably. Symptoms can depend on where the cancer develops.

A retrospective observational study of rapid titration of venetoclax (VEN) in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). This is an ASCO Meeting Abstract from the ...

U.S. FDA Grants to Wugen’s WU-CART-007 Breakthrough Therapy Designation for Treatment of Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia / T Cell Lymphoblastic Lymphoma -- Breakthrough ...

New EORTC guidelines establish meaningful change thresholds for symptom burden, physical condition/fatigue, and worries/fears in R/R CLL or SLL patients. Thresholds help identify significant ...

Acute lymphoblastic leukemia (ALL) may be confused with different types of hematological conditions. Confusion of ALL diagnosis with acute myeloid leukemia (AML), hairy cell leukemia and malignant ...

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease Clinical trials frequently include multiple ...

What Is It, and Why Does It Matter? The FDA has approved a new combination treatment for adults with certain cancers of the blood and lymphatic system. The targeted regimen combines Calquence ...

SAN FRANCISCO and SUZHOU, China, March 1, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...